Literature DB >> 11520459

Sulfation of L-selectin ligands by an HEV-restricted sulfotransferase regulates lymphocyte homing to lymph nodes.

S Hemmerich1, A Bistrup, M S Singer, A van Zante, J K Lee, D Tsay, M Peters, J L Carminati, T J Brennan, K Carver-Moore, M Leviten, M E Fuentes, N H Ruddle, S D Rosen.   

Abstract

Lymphocytes home to lymph nodes, using L-selectin to bind specific ligands on high endothelial venules (HEV). In vitro studies implicate GlcNAc-6-sulfate as an essential posttranslational modification for ligand activity. Here, we show that genetic deletion of HEC-GlcNAc6ST, a sulfotransferase that is highly restricted to HEV, results in the loss of the binding of recombinant L-selectin to the luminal aspect of HEV, elimination of lymphocyte binding in vitro, and markedly reduced in vivo homing. Reactivity with MECA 79, an adhesion-blocking mAb that stains HEV in lymph nodes and vessels in chronic inflammatory sites, is also lost from the luminal aspects of HEV. These results establish a critical role for HEC-GlcNAc6ST in lymphocyte trafficking and suggest it as an important therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520459     DOI: 10.1016/s1074-7613(01)00188-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  53 in total

Review 1.  Biomechanics of leukocyte rolling.

Authors:  Prithu Sundd; Maria K Pospieszalska; Luthur Siu-Lun Cheung; Konstantinos Konstantopoulos; Klaus Ley
Journal:  Biorheology       Date:  2011       Impact factor: 1.875

Review 2.  L-Selectin ligands in lymphoid tissues and models of inflammation.

Authors:  Adil I Khan; R Clive Landis; Rajneesh Malhotra
Journal:  Inflammation       Date:  2003-10       Impact factor: 4.092

3.  Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules.

Authors:  Espen S Baekkevold; Myriam Roussigné; Takeshi Yamanaka; Finn-Eirik Johansen; Frode L Jahnsen; François Amalric; Per Brandtzaeg; Monique Erard; Guttorm Haraldsen; Jean-Philippe Girard
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

4.  A small-molecule switch for Golgi sulfotransferases.

Authors:  Christopher L de Graffenried; Scott T Laughlin; Jennifer J Kohler; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-17       Impact factor: 11.205

5.  Human L-selectin preferentially binds synthetic glycosulfopeptides modeled after endoglycan and containing tyrosine sulfate residues and sialyl Lewis x in core 2 O-glycans.

Authors:  Anne Leppänen; Ville Parviainen; Elina Ahola-Iivarinen; Nisse Kalkkinen; Richard D Cummings
Journal:  Glycobiology       Date:  2010-05-27       Impact factor: 4.313

6.  Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma.

Authors:  Steven D Rosen; Durwin Tsay; Mark S Singer; Stefan Hemmerich; William M Abraham
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 7.  Lymphatic function and immune regulation in health and disease.

Authors:  Shan Liao; Timothy P Padera
Journal:  Lymphat Res Biol       Date:  2013-09-11       Impact factor: 2.589

8.  Initiation of protein O glycosylation by the polypeptide GalNAcT-1 in vascular biology and humoral immunity.

Authors:  Mari Tenno; Kazuaki Ohtsubo; Fred K Hagen; David Ditto; Alexander Zarbock; Patrick Schaerli; Ulrich H von Andrian; Klaus Ley; Dzung Le; Lawrence A Tabak; Jamey D Marth
Journal:  Mol Cell Biol       Date:  2007-10-08       Impact factor: 4.272

9.  Glycosylation might provide endothelial zip codes for organ-specific leukocyte traffic into inflammatory sites.

Authors:  Jutta Renkonen; Olli Tynninen; Pekka Häyry; Timo Paavonen; Risto Renkonen
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  L-selectin ligands in human endometrium: comparison of fertile and infertile subjects.

Authors:  L Margarit; D Gonzalez; P D Lewis; L Hopkins; C Davies; R S Conlan; L Joels; J O White
Journal:  Hum Reprod       Date:  2009-07-22       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.